(2) The extent of decrease of serum hepcidin levels was a strong predictor of symptom improvement in a dose-dependent manner after 12 weeks of dopaminergic treatment, independent of age, sex, CRP, sleep quality, insomnia, daytime sleepiness, depression and anxiety. Here, HAMP is linked to insomnia measurement.